355 results about "Sorafenib" patented technology

The present invention is directed to compositions comprising a nanoparticulate sorafenib, or a salt, such as a sorafenib tosylate, or derivative thereof, having improved bioavailability. The nanoparticulate sorafenib particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of cancer, renal cancer, and related diseases.

The invention relates to an application of antagonizing and/or blocking IL-6/IL-6R/gp130 signaling pathway in treatment of anti-hepatoma, and specifically relates to an application of an antagonist and/or a blocking agent of the IL-6/IL-6R/gp130 signaling pathway and conventional liver cancer treatment drugs (such as cisplatin, doxorubicin and sorafenib) in preparation of anti-hepatoma drug compositions. The composition provided by the invention has significant curative effect for the liver cancers and has the advantages of small toxic and side effects, capability for synergizing with the conventional liver cancer treatment drugs and increasing the effect of the conventional anti-hepatoma treatment, and the like.

The invention relates to an anticancer slow-release gel injection which contains slow-release microspheres containing an angiogenesis inhibitor, an amphiphilic block polymer, a solvent and a slow-release agent, wherein the composition of the amphiphilic block polymer and the non-organic solvent exhibit the property of temperature-sensitive gelation. After the in vivo injection, the injection turns into a stagnant and biodegradable water-insoluble gel and the gel slowly releases the drug contained therein for a plurality of weeks to a plurality of months. After the intratumoral or peritumoral injection, the anticancer slow-release gel injection can significantly reduce the general drug reactions and is used for treating tumors of different stages. The angiogenesis inhibitor is selected from SU5416, SU6668, bosutinib, sprycel, erlotinib, vandetanib, gefitnib, canertinib, lapatinib, lestaurtinib, masitinib, vatalanib, mubritinib, tandutinib, nilotinib, marimastat, nilotinib, pelitinib, telatinib, sunitinib, sorafenib, zarnestra, sirolimus, imatinfb, lenalidomide and thalidomide.

The present invention relates to, for example, (1) a novel method for identification of clinically useful serum and/or tumor biomarkers and expression signatures that can be used for detection, prognostication and guidance for the treatment of patients with hepatocellular carcinoma (HCC); and (2) discovery of an expression signature that can be used to monitor and/or study the efficacy of a chemotherapeutic regimen, such as, for example, sorafenib (solely or in combination with other agents). The present invention also provides a method for predicting clinical outcomes, such as, for example, overall survival (OS), time to progression (TTP) and/or likelihood of benefitting from a chemotherapeutic treatment (i.e., sorafenib) in HCC patients based on the analysis of such biomarkers.

The invention relates to the field of biological medicine, and in particular relates to liver targeted medicine. The medicine is chemical micromolecular medicine connecting galactosamine. The chemicalmicromolecular medicine is medicine for treating liver diseases or liver-related diseases. The chemical micromolecular medicine is prepared from but not limited to thyroxine T3, sorafenib, taxol, regorafenib, lamivudine, entecavir, telbivudine, statins, fibrates, niacin, bile acid sequestrants, other hepatitis virus DNA (RNA) polymerase inhibition compounds and the like. The galactosamine is tervalent acetylgalactosamine. The connection is the direct connection of the galactosamine and the chemical micromolecular medicine or the connection through linking fragments; the linking fragments comprise but not limited to carbon chains, disulfide bonds, pyrophosphate diester, cysteic acid, polypeptide and thioether or valine-citrulline. The medicine provided by the invention has the advantages that the liver targeted performance is improved; the medicine curative effect is enhanced; the toxic and side reactions on other non-targeted tissues are few.

The invention belongs to the production technology for antitumor drugs, and discloses uses of sorafenib and sorafenib salts in preparing drugs for reversing BCRP protein-mediated multidrug resistance of tumors. According to the present invention, the sorafenib and the sorafenib salts are combined with antitumor drugs, such that the sensitivity of multidrug resistant tumor cells to the antitumor drugs are recovered; the prepared drugs are applicable for providing combination chemotherapy for the clinical chemotherapy resistant patients or preventing the drug resistance of the tumor cells from generation.

The invention is based upon the discovery that the mitogen-activated protein kinase (MAPK) pathway can increase CA9 expression independently of HIF-1, as well as increasing CA9 expression under HIF-1-dependent pathways initiated by hypoxia or high cell density. Disclosed herein are novel therapeutic methods for treating preneoplastic/neoplastic diseases associated with abnormal MN/CA IX expression, using MAPK pathway inhibitors. Preferably, the MAPK pathway inhibitors are raf kinase inhibitors, particularly the raf kinase inhibitor Sorafenib. Further disclosed are methods for patient therapy selection for MAPK pathway inhibitors, preferably in combination with other cancer therapies, based on detection of abnormal MN/CA9 gene expression in preneoplastic/neoplastic tissues.

The invention discloses a method for industrial production of a sorafenib tosylate polymorphic substance I. The method comprises the following steps: by adopting N-methyl-4-chloro-pyridine carboxamide and p-aminophenol as raw materials, adding a proper amount of alkali to obtain an intermediate 4-(4-aminophenoxy)-N-methyl-2-pyridine carboxamide by virtue of nucleophilic substitution reaction in an organic solvent, performing condensation on 4-(4-aminophenoxy)-N-methyl-2-pyridine carboxamide and 4-chloro-3-benzenyl trifluoride isocyanate to obtain free alkali of sorafenib, finally performing back-flow and salification with p-toluenesulfonic acid in a mixed solvent of acetone and acetonitrile, and cooling and crystallizing to obtain sorafenib tosylate of the polymorphic substance I. Compared with the prior art, the scheme of the method disclosed by the invention is simple and safe to operate, is mild in reaction condition, and does not need crystal form transformation steps; an obtained product is single and stable in crystal form and high in purity, and is suitable for large-scale industrial production.

The invention relates to a preparation method of sorafenib. The method of the invention comprises the following steps: reacting 4-chloro-3-trifluoromethyl-aniline or acid addition salts of 4-chloro-3-trifluoromethyl-aniline with an acylating chlorination reagent by a one-pot method in the presence of alkali at -10 DEG C-35 DEG C to obtain an N-chloroformyl-4-chloro-3-trifluoromethyl-aniline intermediate, and then directly allowing the intermediate to carry out an ammonolysis reaction with 4-(4-amino phenoxyl)-N-methyl-2-pyridine carboxamide to obtain sorafenib with high yield. The process is simple in operation, short in production period, and high in yield, and the obtained product has a purity of more than 98%.

The invention provides an application of a compound containing tyrosine kinase inhibitor and resveratrol in preparing antitumor drugs. The application is characterized in that the tyrosine kinase inhibitor is selected from one of imatinib, gefitinib, erlotinib hydrochloride tablets, sorafenib, dasatinib tablets and tasigna or pharmaceutically acceptable salts or solvates or pharmaceutically acceptable salt solvents thereof; the tumor is selected from one of gastric cancer, liver cancer, lung cancer, kidney cancer, cervical cancer, pancreatic cancer, breast cancer, esophagus cancer, nasopharynxcancer and ovarian cancer; the mole ratio of resveratrol to tyrosine kinase inhibitor is (1-100):1.

The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.

A targeted sustained-release microsphere vascular embolizing agent, the production method and the use thereof are disclosed. The microsphere comprises sodium alginate as the carrier and sorafenib as the targeted anti-tumor medicine and sorafenib is encapsulated by sodium alginate. The weight ratio of sorafenib to sodium alginate is 1:1˜1:30. The microspheres are used for manufacturing medicament for the treatment of solid tumors with advantages including high medicine concentration in the target regions with reduced systemic dosage and toxic and side effects.

The invention discloses a method for preparing sorafenib. 2-picolinic acid is subjected to chlorination, esterification and methylamination to form a key intermediate, namely 4-chloropyridine-N-methyl-2-formamide, the intermediate and p-aminophenol are subjected to coupled reaction under alkaline condition, and a reaction product is reacted with 4-chloro-3-trifluoromethyl phenyl isocyanate to form a target compound.

The invention provides a synthesis method for sorafenib. The synthesis method is characterized by comprising the following steps: (1) dissolving the raw materials of 4-chlorine-3-trifluoromethylaniline and CDI into an organic solvent, reacting for 2 hours under theat a reaction temperature of 15-40 DEG C, and obtaining the intermediate N-(4-chlorine-3-trifluoromethylaniline)-1H-glyoxaline-1-acid amide; (2) adding a raw material of 4-(4-aminophenoxy)-N-methyl picolinamide, continuously reacting for 1 hour under the same condition, and post-processing, so thatso as to obtain the sorafenib is obtained. Compared with the known synthesis process, the synthesis method provided by the invention is simple to operate, the nitrogen protection is eliminated, and the post-processing in the first step is eliminated; by changing the solvent types, the reaction time is shortened greatly, and the yield is increased obviously, so that industrialized production is more facilitated.

The invention belongs to the field of pharmaceutical chemicals, and particularly relates to a crystal form A of 4-[4-[3-(4-chloro-3-trifluoromethyl phenyl) ureide) phenoxy]-pyridine-2-formamide (sorafenib) with antitumor activity and a preparation method thereof. The purity of a crystal form A of Sorafenib prepared according to the invention is high, and is over 99.0%, an X-ray powder diffraction of the crystal form expressed by a 2theta angle has characteristic peaks at angles of 11.2-11.6 degrees, 11.4-11.8 degrees, 18.4-18.8 degrees, 22.3-22.7 degrees, 24.6-25.0 degrees and 29.5-29.9 degrees, and the crystal form is uneasy to decompose at a temperature of 25-50 DEG C, so that the crystal form shows good stability.

The invention relates to quinazolinyl-aryl urea derivatives with antitumor function disclosed as general formula (II) and application thereof. The substituent group in the general formula (II) is defined in the specification. By using sorafenib and gefitinib as lead compounds, the pharmacophore-uramido group of the sorafenib is retained; and meanwhile, the quinazoline rings in the gefitinib and other EGFR-TKIs are retained to synthesize a series of quinazolinyl-aryl urea derivatives. The in-vitro activity test proves that parts of the compounds have excellent antitumor activity, and the compounds have higher research and practical values. (II).

The invention discloses a novel method for synthesizing sorafenib. The method comprises the following steps: using a (4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide) compound II and a (4-chloro-3-trifluoromethylphenyl-carbamoyl-imidazole) compound III as raw materials, and reacting in an organic solvent inert to the compound III to produce a sorafenib crude product; then, dissolving the sorafenib crude product by the organic solvent and an organic or inorganic acid, and adding a solvent into which sorafenib is difficult to dissolve to enable the sorafenib to be separated out, so as to obtain a sorafenib pure product. The novel method is simple in technical process, ensures high product purity, facilitates operation and is suitable for large-scale industrial production.

The invention discloses a sorafenib lipidosome freeze-dried injection for injection and a preparation method thereof. The freeze-dried injection is prepared from the following components in molar ratio: 1 mol of sorafenib, 5-60 mol of phospholipid, 1-30 mol of cholesterol, 1-60 mol of phosphatidyl glycerol, 1-10 mol of a polyethylene glycol surfactant and 50-400 mol of a freeze-drying protecting agent. The preparation method comprises the following steps: sequentially dissolving phospholipid, cholesterol, phosphatidyl glycerol, polyethylene glycol surfactant and sorafenib in an organic solvent in proportion; then, carrying out rotary and vacuum evaporation on the obtained organic solution in a round bottom glass bottle, so that a uniform thin film is formed on the inner wall of the glass bottle; then, adding a buffer liquid with the pH of 7-10 into the glass bottle to be continuously stirred to form a suspension; reducing the grain size of the suspension by an ultrasonic or high-pressure homogenizing method; and adding the freeze-drying protecting agent and freeze-drying. The sorafenib lipidosome disclosed by the invention remarkably improves the bioavailability and is stable in property, and the encapsulation efficiency can reach over 96%.

The invention discloses a novel sorafenib tosylate polycrystalline form A and a preparation method thereof. A DSC spectrum of the crystal form comprises a transition peak at 198.0-207.5 DEG C and a melting decomposition peak at 238.5-247.5 DEG C. The invention also discloses a method for preparing the sorafenib tosylate (I) polycrystalline form A from sorafenib free base and p-toluenesulfonic acid in a mixed solvent of alcohol and water. The method has the advantages of good repeatability, simple operation, high product yield, high purity, and suitability for industrialized productions.

The invention provides a sorafenib preparation. The sorafenib preparation includes active ingredients and macromolecular cosolvent. The active ingredients are selected from at least one of sorafenib, sorafenib salt, a sorafenib derivative or a prodrug of the sorafenib derivative. The macromolecular cosolvent is provided with vinyl acetate radical groups. The sorafenib preparation has the advantage that the bioavailability of the drug active ingredients is high.